제산제 시장 : 약제 클래스별, 제제 유형별, 유통 채널별, 지역별 보고서(2024-2032년)

The global antacids market size reached US$ 6.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 3.5% during 2024-2032. The market is experiencing growth mainly because of the expansion of retail pharmacies, preference for OTC drugs, and rising number of patients experiencing gastroesophageal reflux disease (GERD) are impelling the growth of the market.

Antacids Market Analysis:

Major Market Drivers: People suffering from GERD is increasing around the world, which is catalyzing the demand for antacids. This represents one of the key factors propelling the market growth.

Key Market Trends: The launch of flavored and chewable antacids drugs by key players like watermelon mint, fruity cereals, and strawberry milkshake is positively impacting the antacids market revenue.

Geographical Trends: Asia Pacific is the largest regional market for antacids because of the rising healthcare expenditure, aging population, and healthcare sector expansion.

Key Players: Some of the major market players in the antacids industry include Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., among many others.

Challenges and Opportunities: Challenges in the antacids market are the presence of alternative treatment for acid reflux, while opportunities lie in emerging markets and innovative formulations to treat digestive issues.

Antacids Market Trends:

Gastroesophageal reflux disease's (GERD) impact

• 783.95 million people were impacted by GERD in 2019 claimed by the report of the National Library of Medicine 2022. The more people going through the suffering of GERD, the more it is driving the demand for antacids. The best treatment for acidity is thought to be antacids because of their several qualities. Individuals are aware about the quick relief provided by antacids and their easy accessibility is further contributing to the antacids market growth.

Changing demographics because of rising geriatric population

Elderly people are understanding the importance of antacids because of their quick relief qualities from acidity. They are, as a result, a regular consumer or buyer of antacids to manage these digestive issues. It may be said that nations with increased aging population rates can have higher sales of antacids worldwide. As claimed by the World Health Organization's (WHO) report of 2022, 1 individual out of 6 will be of 60 years in age or over by 2030 and by 2050. The global population of those aged 60 and over will also reach 2.1 billion, up from 1.4 billion in 2020.

Rising reliance on over the counter (OTC) medicines due to their ease of availability

Non-prescribed remedies are highly preferred in the world to cure mild symptoms, which is catalyzing the antacids demand. Antacids are easily available via pharmacies, grocery stores, and online platforms and as a result play a crucial role in self-medication purposes. The cost-effectiveness and time saving benefits provided by antacids are making them highly suitable for people nowadays. The IMARC Group's research report mentions that the global market for over the counter (OTC) drugs will reach US$ 275.9 Billion by 2032.

Antacids Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug class, formulation type, and distribution channel.

Breakup by Drug Class:

Proton Pump Inhibitors

H2 Antagonist

Acid Neutralizers

Pro-Motility Agents

Proton pump inhibitors accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes proton pump inhibitors, H2 antagonist, acid neutralizers, & pro-motility agents. According to the report, proton pump inhibitors represent the largest segment.

Proton pump inhibitors are so effective and reliable that everyone wants them to cut down on stomach acid and indigestion. Healthcare professionals prescribed them as per the severity of acid reflux, leading to their higher sales. Key players are expanding their market as they know people are gaining knowledge about the positive impact of proton pump inhibitors in the body. For instance, Daewon Pharmaceutical introduced its first proton pump inhibitor medicine in Korea in 2022, known as Escorten.

Breakup by Formulation Type:

Tablet

Liquid

Powder

Others

Tablet holds the largest share of the industry

A detailed breakup and analysis of the market based on the formulation type have also been provided in the report. This includes tablet, liquid, powder, and others. According to the report, tablet accounts for the majority of the market share.

Easy storage, transportation, and administration are some benefits provided by tablets make them highly preferable among individuals. Tablets are hassle-free, as they can be easily consumed with water anywhere or on the go. Whether at office, home, or travel, people can get quick relief from acidity or indigestion through tablet drugs. The extended shelf life of tablets is viewed as another benefit compared to liquid or powder formulation type. Various tablets formulations present in the antacids market like chewable, delayed release, and effervescent are further creating a strong consumer base.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Others

Retail pharmacies represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and others. According to the report, retail pharmacies dominate the market.

In the first place, cities, suburbs, and rural areas all have numerous retail pharmacies around the world. Antacids as OTC drugs are highly popular & retail pharmacies are a significant outlet to purchase antacids. Secondly, the inclusion of a wide variety of antacids drugs in retail pharmacies can cater to several patients according to their preferences and demands. Thirdly, the focus of leading competitors in the retail pharmacy market on acquisition & expansion to increase their reach. The acquisition of Pharmaca by Medly Pharmacy in 2021 to deliver 360-degrees pharmacy services is one such example.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Asia Pacific leads the market, accounting for the largest antacids market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific enjoys the leading position in the market.

The densely populated countries like India and China are the largest markets for antacids in this region, as these countries are undergoing lifestyle shifts and Western food habits, which generally results in acid reflux and indigestion. Moreover, aging population in the region is viewed as an antacids market recent opportunities due to their high susceptibility to digestive issues. In line with this, lots of key players are present in the Asia Pacific region that are highly competitive and focus on partnerships and acquisition to expand their market. This was done by Dr. Reddy's Laboratories, a pharma company in India, when it acquired MenoLabs from Amyris Inc. in 2024 to cater to the evolving needs of people in the Asia Pacific region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major antacids companies have also been provided. Some of the major market players in the antacids industry include:

Abbott Laboratories

AstraZeneca plc

Bayer AG

Boehringer Ingelheim International GmbH

Dr. Reddy's Laboratories Ltd.

GlaxoSmithKline plc

Johnson & Johnson

Pfizer Inc.

Procter & Gamble Company

Reckitt Benckiser Group PLC

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited.

(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)

The development of new formulations and product variants is done by key players through research and development (R&D) activities. They are introducing antacid drugs with flavors such as Fruity Cereal to meet the evolving demands of consumers. Top companies are taking advantage of elevated awareness about gastrointestinal health among people in developing countries. They are also eyeing on acquiring small businesses in the market while creating opportunities via antacids market recent developments. Using the digital health solutions is the main help method, enabling them to provide better health results. One such example was presented by AstraZeneca in November 2023, which it launched Evinova, a health-tech business, to offer advanced digital health solutions.

Antacids Market News:

In 2022: Zydus Lifesciences received approval from the USFDA to introduce Famotidine tablets, which is a histamine H2 receptor blocker and plays a vital role in reducing acid amount in the stomach.

Key Questions Answered in This Report

• 1. How big is the global antacids market?
• 2. What is the expected growth rate of the global antacids market during 2024-2032?
• 3. What are the key factors driving the global antacids market?
• 4. What has been the impact of COVID-19 on the global antacids market?
• 5. What is the breakup of the global antacids market based on the drug class?
• 6. What is the breakup of the global antacids market based on the formulation type?
• 7. What is the breakup of the global antacids market based on the distribution channel?
• 8. What are the key regions in the global antacids market?
• 9. Who are the key players/companies in the global antacids market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Antacids Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Proton Pump Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 H2 Antagonist
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Acid Neutralizers
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Pro-Motility Agents
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Formulation Type

• 7.1 Tablet
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Liquid
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Powder
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AstraZeneca plc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bayer AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Boehringer Ingelheim International GmbH
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Dr. Reddy's Laboratories Ltd.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 GlaxoSmithKline plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Johnson & Johnson
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Procter & Gamble Company
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Reckitt Benckiser Group PLC
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Sanofi S.A.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Sun Pharmaceutical Industries Ltd.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis
  • 14.3.13 Takeda Pharmaceutical Company Limited
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis